Co‐Prescribing of Potentially Interacting Drugs during Warfarin Therapy – A Population‐Based Register Study
- 19 January 2015
- journal article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 117 (2) , 126-132
Abstract
We analysed the occurrence of co-prescribing of potentially interacting drugs during warfarin therapy in the community-dwelling population of Finland. We identified drugs having interaction potential with warfarin using the Swedish Finnish INteraction X-referencing drug-drug interaction database (SFINX) and obtained data on drug purchases from the nationwide Prescription Register. We defined warfarin users as persons purchasing warfarin in 2010 (n = 148,536) and followed them from their first prescription in 2010 until the end of the calendar year. Co-prescribing was defined as at least 1-day overlap between warfarin and interacting drug episodes. In addition, we identified persons who initiated warfarin therapy between 1 January 2007 and 30 September 2010 (n = 110,299) and followed these incident users for a 3-month period since warfarin initiation. Overall, 74.4% of warfarin users were co-prescribed interacting drugs. Co-prescribing covered 46.4% of the total person-years of warfarin exposure. Interacting drugs that should be avoided with warfarin were co-prescribed for 13.4% of warfarin users. The majority of the co-prescriptions were for drugs that are not contraindicated during warfarin therapy but require special consideration. Among incident users, 57.1% purchased potentially interacting drugs during the 3-month period after initiation, while 9.0% purchased interacting drugs that should be avoided with warfarin. To conclude, the occurrence of co-prescribing of potentially interacting drugs was high during warfarin therapy. Our findings highlight the importance of close monitoring of warfarin therapy and the need for further studies on the clinical consequences of co-prescribing of interacting drugs with warfarin.Keywords
Funding Information
- The Social Insurance Institution of Finland (11/26/2012)
This publication has 55 references indexed in Scilit:
- Current strategies to minimize the bleeding risk of warfarinJournal of Blood Medicine, 2013
- Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical TrialJournal of the American Heart Association, 2013
- Rates of hemorrhage during warfarin therapy for atrial fibrillationCanadian Medical Association Journal, 2012
- National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011Circulation: Cardiovascular Quality and Outcomes, 2012
- Antidepressant-Warfarin Interaction and Associated Gastrointestinal Bleeding Risk in a Case-Control StudyPLOS ONE, 2011
- Who receives anticoagulant treatment with warfarin and why? A population-based study in FinlandScandinavian Journal of Primary Health Care, 2010
- Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding RiskThe American Journal of Medicine, 2010
- Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleedingCanadian Medical Association Journal, 2007
- The impact of simvastatin on warfarin disposition and dose requirementsJournal of Thrombosis and Haemostasis, 2006
- Direct costs of warfarin treatment among patients with atrial fibrillation in a Finnish health care settingCurrent Medical Research and Opinion, 2006